Aquavit Pharmaceuticals, Inc. has launched a cutting-edge technology the AQUAGOLD® fine touch™. It is a first-of-its-kind direct dermal application technology.
The unique features of the AQUAGOLD® fine touch™ is that it minimises risks of hurting and swelling in the facial skin. Therefore it makes treatment around the mouth, eyes etc., much easier. These areas are usually difficult to treat especially under traditional methods of delivery which are available in the market.
This technology is a long-awaited solution for the unmet needs of the more than 11 billion dollar medical aesthetics market and the 30 billion dollar vitamin and mineral market.
Depending on the growing demands of the patients, it can be used with microbotox, hyaluronic acid-based fillers and vitamin combinations as well, according to Dr. David Shafer, Chief Medical Technology Officer of Aquavit Pharmaceuticals.
